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Abstract 
The aim of our study was to look for alternative predictive biomarkers for breast cancer management in limited 
resource setup. A comprehensive analysis of circulating cell-free DNA (CCFD) in serum at baseline was performed 
to assess its prognostic potential. Quantitative polymerase chain reaction (qPCR) of ALU sequences using ALU115 
and ALU247 primers was carried out in patients (N: baseline 148, postoperative 47) and 51 healthy controls. Mean 
serum DNA integrity, levels of ALU 247 and levels of ALU 115 were significantly higher in patients than in healthy 
females. No significant differences were observed in the levels ALU 247 and ALU 115 between stage IV and earlier 
stages of the disease. The DNA integrity was significantly higher in stage IV than earlier stages. A significant decrease 
in DNA integrity was observed after surgery (pre: 0.55 ± 0.23 vs post: 0.43 ± 0.30; P = 0.002) while no such change 
could be observed for ALU 247 and ALU 115. Baseline DNA integrity was significantly higher in relapsed patients 
than in patients who were free of disease (P = 0.005). Higher baseline DNA integrity was also indicated, though 
statistically not significant, in patients who died (P = 0.14). In contrast, ALU 247 and ALU 115 levels were decreased 
in died patients as compared to survivors (24.8 ± 34.80 vs 73.5 ± 170.83, P = 0.02 for ALU 247 and 41.0 ± 47.99 
vs 159.5 ± 299.54, P = 0.005 for ALU 115). Baseline levels of ALU 115 and ALU 247 were lower in relapsed patients, 
though statistically not significant. In univariate analysis, the only clinic-pathological parameter associated with dis-
ease prognosis was tumor size. The hazards of 5-year overall mortality was 3.60 (95 % CI: 1.03 12.53, P = 0.03) among 
patients with lower baseline serum levels of CCFD (ALU 247 < 21 and ALU 115 < 41). Similarly the 4 year hazards for 
recurrence was 2.30 (95 % CI: 0.96 5.52, P = 0.05) among patients with higher DNA integrity. Baseline serum levels of 
CCFD and its integrity were found to be potential prognostic biomarkers in patients of primary breast cancer at our 
centre.
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Background
Breast cancer is the most common cancer in women 
worldwide, including India, and is the leading cause of 
death from cancer among women globally (Ferlay et  al. 
2015). It is estimated that 145,000 new cases are diag-
nosed and 70,000 deaths occur annually in India (Ferlay 
et al. 2015). The average age at diagnosis is 43–46 years 
in Indian women, about 10  years lower than the age in 
the western world (Saxena et  al. 2005) and in Asian 
population, increase in incidence of breast cancer is 
associated with increased mortality (Ferlay et  al. 2015). 
Improvement in treatment strategies for breast cancer 
has resulted in longer survival of patients, with a need 
for suitable and optimal follow-up, mainly during the 
first 3  years, which is associated with locoregional and 
distant recurrences (Clarke and Martinez 1992). At pre-
sent there is no improvement in the surveillance methods 
used to detect the recurrences and the serological mark-
ers available have not improved the rate of recurrences 
(Duffy 2006). Hence, there is a need for developing new 
biomarkers which can be used as valuable tools in iden-
tifying high risk patients, to predict disease prognosis 
and thus have an impact in patient management. In view 
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of the infrastructural limitations and affordability of the 
facilities etc. (Dinshaw et al. 2005; Okonkwo et al. 2008), 
alternative approaches to breast cancer monitoring are 
clearly needed.
Presence of circulating cell-free DNA (CCFD) in 
blood, though reported in 1948 (Mandel and Metais 
1948), was rediscovered after 30  years in autoimmune 
disorders (Tan et  al. 1966) and in cancer (Leon et  al. 
1977). Its presence in blood is studied by quantification, 
mutation, methylation as well as microsatellite altera-
tion (Jung et  al. 2010). The higher levels of cell-free 
DNA are found in serum or plasma of cancer patients 
than in healthy controls (Sunami et  al. 2008; Stötzer 
et al. 2014). In healthy individuals, the main source of 
cell free DNA in circulating blood is through apoptosis, 
whereas in cancer patients it results from both apop-
tosis as well as by necrosis (Jahr et al. 2001). The major 
portion of CCFD in cancer patients is of apoptotic ori-
gin i.e. shorter fragments, therefore elevated levels of 
longer fragments of DNA in blood has been reported to 
be a good marker for the presence of malignant tumor 
DNA (Jahr et al. 2001; Umetani et al. 2006c; Diehl et al. 
2008). Based on this logic, DNA integrity,  the ratio of 
longer to shorter DNA fragments, has been assessed 
for its diagnostic and prognostic potential in cancer 
patients (Wang et  al. 2003; Umetani et  al. 2006a, c; 
Holdenrieder et  al. 2008; El-Shazly et  al. 2010). DNA 
integrity  has been reported to be significantly higher 
in patients with metastatic breast cancer as compared 
to patients with locally confined breast cancer and 
benign controls (Stötzer et  al. 2014). It was found  to 
predict tumor progression, regional LN metastases in 
primary breast cancer patients (Umetani et  al. 2006a) 
and shorter disease free interval in patients with naso-
pharyngeal cancer (Chan et al. 2008). However, recent 
evidence suggests that it has no role in predicting the 
response to therapy in breast cancer patients who 
received neoadjuvant chemotherapy (Lehner et  al. 
2013). The diverse results in literature regarding the 
predictive ability of CCFD in primary breast cancer are 
on account of the fact that most of studies have evalu-
ated either the absolute levels of CCFD or DNA integ-
rity (Jung et al. 2010).
In the present study, the aim was to assess the utility 
of CCFD as an alternative prognostic tool in the limited 
resource setup. We studied the baseline serum levels of 
absolute DNA, longer fragments of DNA as well as its 
integrity in primary breast cancer patients and compre-
hensively evaluated the predictive ability of each bio-
marker with overall survival (OS) as well as disease free 
survival (DFS) of these patients.
Methods
Patient selection
We included newly diagnosed primary breast cancers 
attending the outpatient clinic of the department of 
Medical Oncology at Institute Rotary Cancer Hospital, 
All India Institute of Medical Sciences, New Delhi, India 
during April 2009 to February 2012. A written informed 
consent was obtained from all participants and the Insti-
tute’s Ethics Committee approved the study.
Inclusion criteria




Venous blood samples (10 ml in a serum separator tube) 
were collected from cases with American Joint Com-
mittee on Cancer (AJCC) stage I to IV of primary breast 
cancers. A subset of patients was sampled 1 month after 
modified radical mastectomy. In addition, blood samples 
were also collected from healthy female volunteers. All 
samples were processed immediately.
Serum preparation for direct quantitative PCR (qPCR)
The serum was separated by centrifugation (1,000×g, 
15  min) and was passed through a 13-mm serum filter 
(Millipore) to remove any contaminating cells, divided 
into aliquots in clean polypropylene tubes and stored at 
−80°C until processing. Serum preparation for qPCR was 
performed as described by Umetani et al. (2006a) Briefly, 
serum proteins which might hinder the qPCR results by 
binding to template DNA or DNA polymerase were deac-
tivated by mixing 20 µL of each serum sample with 20 µL 
of a preparation buffer that contained 2.5% of tween 20, 
50 mmol/L Tris, and 1 mmol/L EDTA. This mixture was 
digested with proteinase K (20  µg) solution for 50  min 
(Promega) at 56°C, followed by 5 min of heat deactivation 
and insolubilization for 10 min at 95°C. After subsequent 
centrifugation of 10,000×g for 5 min, 0.2 µL of superna-
tant was used as a template for each qPCR reaction.
Quantitative PCR of ALU repeats
Quantitative PCR was performed as described previ-
ously (Umetani et  al. 2006a). Two primer sets ampli-
fying ALU sequences were used to quantify the levels 
of a 115  bp DNA amplicon (ALU115 amplifying both 
short and long DNA fragments), and a 247  bp ampli-
con (ALU247, amplifying only large DNA fragments), 
the ALU115 primers were forward: 5_-CCTGAGGT 
CAGGAGTTCGAG-3′ and reverse: 5′-CCCGAGT 
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AGCTGGGATTACA-3′; and ALU247 primers were for-
ward: 5′-GTGGCTCACGCCTGTAATC-3′ and reverse: 
5′-CAGGCTGGAGTGCAGTGG-3′. ALU115-qPCR 
values represent the total amount of CCFD in serum, 
whereas ALU247-qPCR values represent amounts of DNA 
in serum released from non-apoptotic cells. DNA integ-
rity was calculated as the ratio of qPCR results (ALU247-
qPCR/ALU115-qPCR). As the annealing sites of ALU115 
are within the ALU247 annealing sites, thus the ratio of 
ALU247 to ALU115 is termed as DNA integrity. It char-
acterizes the fragmentation pattern of CCFD (i.e. the DNA 
integrity is 1 if template DNA is not truncated and 0 if 
DNA is completely truncated to fragments smaller than 
247  bp). Quantitative PCR was carried out in duplicates 
on LightCycler2 (ROCHE). Each 20 μl reaction consisted 
of 1 × LightCycler DNA Master SYBR Green I (ROCHE), 
400  nM forward and reverse primers, 5  mM MgCl2 and 
0.2 μl of DNA sample. PCR amplification was carried out 
according to manufacturer’s instruction which was 95°C 
for 30 s, followed by 45 cycles at 95°C for 0 s and 57/55°C 
for 10  s and 72 for 5  s followed by melting curve analy-
sis to confirm specificity of the PCR products. Each run 
included fivefold dilutions of an external standard (healthy 
leukocyte DNA) and negative control (without template).
Clinical follow‑up
Starting from the completion of treatment, patients were 
followed up every 3  months during the first year, every 
6  months during the second year, and then yearly until 
relapse with clinical, biochemical, and radiological examina-
tions. All the patients received multimodality treatment in 
the form of surgery (for stages I–III), chemotherapy, radio-
therapy and hormonal ±  targeted therapy whenever indi-
cated. Overall survival (OS) was defined as the period from 
date of diagnosis to death and Disease Free Survival (DFS) 
was defined as the period from end of treatment to relapse.
Statistical analysis
Data was expressed as mean ± standard deviation (SD). 
Differences between groups were assessed by using Stu-
dent’s t test. Differences in study parameters between pre 
and post-operative groups were assessed using paired 
t-test. Log transformed values were used for analyses. A 
P value ≤0.05 was considered as significant. OS and DFS 
were assessed by Kaplan–Meier survival analysis. The 
association of CCFD and DNA integrity with survival 
was evaluated by Cox proportional hazard regression 
model. All statistical analysis was done using Stata 12.1.
Results
Patient characteristics
One hundred forty-eight patients and 51 healthy female 
volunteers were enrolled. Repeat serum samples from 
47 post operative patients were studied. Mean age of the 
patients was 48.2 ± 10.79 years and that of controls was 
42.3 ± 11.4 years. Average tumor size was 4.6 ± 2.70 cm 
among patients undergoing surgery. Patient character-
istics are summarized in Additional file 1: Table  S1. As 
can be seen most of the cases had ductal carcinoma and 
about a fifth of them were triple negative.
Circulating cell‑free DNA levels—ALU247 (qPCR values 
of longer DNA fragments)
Primary breast cancers showed significantly (P  <  0.001) 
higher levels of ALU247 as compared to healthy 
females. Levels of ALU247 were highest in stages I–III 
(63.8 ± 154.77), least in healthy controls (11.4 ± 9.01) and 
patients of stage IV showed in between (48.4 ±  63.73). 
The difference in the levels between stage IV and earlier 
stages was not statistically significant. Levels of ALU247 
were significantly elevated in stages I–III and also in 
Stage IV as compared healthy controls (Additional file 1: 
Table S2).
The levels of ALU247 did not alter significantly after 
the surgery (pre: 29.9 ± 49.38 vs post: 24.7 ± 23.49 pg/
μL, P = 0.15, N = 47) among cases of stages I-III. Post-
operative ALU247 levels of these cases were still higher 
than the levels in healthy controls (24.7  ±  23.49 vs 
11.4 ± 9.01, P = 0.06).
The mean baseline levels of ALU247 were elevated in 
patients of stages I–III without relapse as compared to 
patients with relapse, though not statistically significant 
(Additional file 1: Table  S3), but significantly elevated 
in survivors (73.5  ±  170.83) than in patients who died 
(24.8 ± 34.80). In contrast, no statistically significant dif-
ferences were observed between died and alive patients 
of stage IV (Additional file 1: Table S3).
ALU115 (qPCR values of both shorter and longer DNA 
fragments)
The levels of ALU115 were significantly higher in patients 
than in healthy controls (136.3 ± 272.50 vs 39.1 ± 22.96, 
P = 0.05). The levels were similar in cases of stages I–III 
and stage IV.
Post surgical levels of ALU115 though elevated, were 
not significantly different from the pre-surgical lev-
els (126.1  ±  249.22 vs 67.7  ±  123.42  pg/μL, P  =  0.15, 
N  =  47) among cases of stages I-III (Additional file 1: 
Table  S2). The post-surgical levels of ALU115 were 
significantly higher than that of healthy controls 
(126.1 ± 249.22 vs 39.1 ± 22.96, P = 0.03).
The relapsed and died patients showed lower levels of 
ALU115 as compared to relapse free and alive patients 
respectively. However, the reduced levels among relapsed 
patients were not significant from the relapse free 
patients. Patients of stage IV did not show any difference 
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in the levels of ALU115 between died and alive patients 
(Additional file 1: Table S3).
DNA integrity (ALU247/ALU115)
The mean serum DNA integrity was significantly ele-
vated in patients than in healthy females (Additional file 
1: Table S2). Further, an increasing trend of DNA integ-
rity was observed from healthy controls (0.35  ±  0.27) 
to breast cancer stages of I–III (0.53 ± 0.23) to stage IV 
cases (0.60 ± 0.26).
DNA integrity levels came down significantly after 
surgery among cases of stage I–III (0.55  ±  0.23 vs 
0.43  ±  0.30; P  =  0.002). The post-operative levels of 
DNA integrity in these patients was comparable to that 
of healthy females (0.43 ± 0.30 vs 0.35 ± 0.27, P = 0.94).
The baseline DNA integrity was significantly higher 
in relapsed patients than patients without relapse 
(0.65 ± 0.23 vs 0.49 ± 0.21, P = 0.005). No significant dif-
ferences were observed between died and alive patients, 
among both stages I–III and stage IV (Additional file 1: 
Table S3).
The analysis of the association of various clinico-
pathological factors with overall survival and disease 
free survival indicated that only the size of the tumor 
(≥4.0  cm) to be associated with poorer overall survival 
(HR: 3.56, 95% CI 1.02–12.02, P = 0.03), Additional file 1: 
Table S4. When each patient was categorized as high or 
low based on the median levels of each biomarker among 
alive patients, only ALU115 showed marginally signifi-
cant association with OS. However, the combination of 
ALU247 and ALU115 showed significant association 
(Additional file 1: Table  S4). Compared to those cases 
of stages I-III with ALU247 ≥ 21 and ALU115 ≥ 41 pg/
µL, cases with either one below the respective cutoff 
values had a HR of 3.6 (95% CI 1.03–12.53), Additional 
file 1: Table  S4. Cases with tumor size  ≥  4.0  cm and 
ALU247 < 21 and/or ALU115 < 41 had a hazards of 6.30 
(95% CI: 2.05–19.36, P = 0.001).
The size of the tumor and DNA integrity showed sig-
nificant association with disease free survival (Additional 
file 1: Table S4). Patients with a tumor size ≥4.0 cm had 
a hazards of 3.4 compared to those with a tumor size of 
<4  cm. Those patients whose DNA integrity was ≥0.48 
had higher hazards of 2.30 (Additional file 1: Table  S4). 
When both the size of tumor and the DNA integrity were 
assessed together, both showed a significant association 
with DFS, HR for size of tumor was 3.91 (95% CI 1.46–
10.48, P  =  0.01); and HR for DNA integrity was 2.85 
(95 % CI 1.18–6.86, P = 0.02).
Discussion
This prospective observational study included a cohort 
of early and locally advanced breast cancers. The 
levels of CCFD in serum were evaluated by qPCR of ALU 
sequences, which are 300 base pair (bp) interspersed 
repeat elements in the human genome, having a copy 
number of approximately 1 million copies per genome 
(Deininger 2011). Serum was used for studying the CCFD 
(ALU247 & ALU115) levels, as it is believed to be bet-
ter source of CCFD than plasma (Umetani et al. 2006b). 
The amount of DNA found in the serum is high with low 
levels of contaminating DNA released from blood cells 
when processed within 8  h after collection (Umetani 
et al. 2006a).
The clearance of apoptotic and necrotic debris by infil-
trating phagocytes is hampered during tumor growth, 
thus resulting in accumulation of cellular debris and 
its secretion into the circulation (Diaz and Bardelli 
2014). In addition, the active secretion of apoptotic and 
necrotic DNA in circulation has also been indicated in 
the increase of CCFD levels in blood (Jahr et al. 2001). A 
number of studies have highlighted the presence of sig-
nificantly elevated levels of CCFD in plasma as well as in 
the serum of patients suffering from breast, colorectal, 
lung and other cancers (Umetani et  al. 2006c; Holden-
rieder et al. 2008; Yoon et al. 2009; Agostini et al. 2012). 
In the present study, we too observed significantly higher 
levels of longer DNA fragments (ALU247), absolute DNA 
(ALU115) as well as higher DNA integrity in breast can-
cer patients than in healthy controls. We observed that 
the DNA integrity was indicative of tumor progression 
which is supported by the study of association between 
DNA integrity and tumor progression in breast cancer 
patients (Umetani et al. 2006a).
The elevated levels of CCFD levels due to trauma reach 
normal levels within 2  h after traumatic injury and the 
half-life of CCFD is approximately 16 min (Lo et al. 1999; 
Lam et al. 2003), so following surgery, a gap of 4–5 weeks 
was given prior to next sampling. Some studies have 
reported that the CCFD levels decrease following surgery 
(Catarino et  al. 2008), whereas others report that there 
is persistence of tumor DNA after surgery in the plasma 
of breast cancer patients (Silva et al. 2002a). We did not 
observe any significant decrease in the levels of ALU247; 
however DNA integrity decreased significantly after sur-
gery which indicates more of apoptotic DNA in circula-
tion. The higher levels of ALU115 observed in patients 
after surgery might be due to the increase in  apoptosis 
associated with wound healing (Greenhalgh 1998; Wu 
and Chen 2014). The persistence of longer fragments of 
DNA after excision of tumor indicates that its presence 
in circulation might be associated with some other body 
mechanism.
The prognostic value of CCFD has only been explored 
in a small number of studies which report that the 
decreasing CCFD levels are associated with early 
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treatment response, e.g. in lung cancer (Gautschi et  al. 
2004), rectal cancer during neo-adjuvant chemo-radi-
ation therapy (Zitt et  al. 2008) and in breast cancer 
(Lehner et al. 2013). In contrast, we did not observe any 
association of post-operative levels of ALU247, ALU115 
and DNA integrity with either OS or DFS (data not 
shown). However, our pre-therapeutic serum levels of 
CCFD demonstrate that percentage of survival was bet-
ter in patients with higher levels of ALU247 as well as 
ALU115. These results are in line with study by Gal et al., 
which show that the breast cancer patients with higher 
concentration of serum DNA had better overall survival, 
which they linked with a better host response to the 
tumor so improved survival rates (Gal et al. 2004).
The persistence of increased DNA integrity observed 
after the treatment in nasopharyngeal tumors indicate 
worse prognosis than patients with reduced DNA integ-
rity (Chan et  al. 2008). However, recently Lehner et  al., 
reported that DNA integrity was not informative of 
therapy outcome in breast cancer patients (Lehner et al. 
2013). In contrast in the present study, we observed that 
the baseline DNA integrity was associated with DFS i.e. 
patients with higher DNA integrity had poorer DFS. 
These results are consistent with the study of Silva et al. 
who reported that cell-free tumor DNA at diagnosis in 
plasma of breast cancer patients is associated with DFS 
(Silva et al. 2002b).
In the present study, we observed that the size was 
the only clinic-pathological marker which was associ-
ated with both the OS and DFS of the patients,  which 
is a well documented prognostic factor of breast cancer 
(Carter et  al. 1989). One study has  reported a border-
line significance between the plasma tumor DNA and 
DFS in multivariate analysis with tumor size, lymph 
node and tumor stage (Silva et  al. 2002b). Our multi-
variable analysis showed that the tumor size and CCFD 
(ALU247, ALU 115) were significant prognostic factors 
associated with 5-year OS, while tumor size in associa-
tion with DNA integrity significantly predicted 4-year 
DFS of primary breast cancer. So tumor size in associa-
tion with CCFD might be helpful in identification of high 
risk patients and their early management.
The varied results regarding the predictive and prog-
nostic utility of CCFD reported in the literature are 
because of the lack of standardized procedures for its 
quantification. In order to validate the clinical utility 
of CCFD, there is a need to harmonize the techniques 
involved in its quantification and also to include well-
powered sample size in study.
In conclusion, our results show that the baseline serum 
levels of ALU247, ALU115 and DNA integrity are higher 
in patients than in healthy controls. An interesting cor-
relation was observed between the baseline levels of 
ALU247, ALU115, DNA integrity and disease prognosis 
in patients (stages I–III). The levels of CCFD (ALU247, 
ALU115) were predictive of 5-year survival whereas the 
DNA integrity was indicative of 4-year DFS. Further 
studies are required to examine the association of levels 
of CCFD with host immune responses and its implica-
tion in the prognosis of breast cancer. The large standard 
deviation of these markers points out that there may be 
many other factors associated with them which need to 
be explored.
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